Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while iShares 20 Plus Year Treasury Bond ETF trades at $84.37. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | TLT | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $92.06 |
52-Week Low | $20.06 | $83.02 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $84.55, down 1.12% on the day, reflecting ongoing bearish pressure in the long-duration Treasury market. Technical indicators are predominantly bearish, with moving averages signaling a strong sell, while oscillators remain neutral. The fund has faced significant drawdowns recently, losing nearly 48% since 2020, but now offers higher starting yields, attracting investor attention amid shifting Fed policy expectations and inflation concerns.
The outlook for TLT hinges on Federal Reserve interest rate decisions and inflation trends. Opportunities exist for yield-seeking investors due to elevated distributions, but risks include potential further rate hikes, prolonged high inflation, and interest rate sensitivity. Market sentiment is mixed, with some analysts seeing value after the steep decline, while others caution about duration risk in a volatile macroeconomic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
